A Simple and Sensitive LC‐MS/MS Method for the Determination of Mobocertinib and Its Metabolite Desmethyl‐Mobocertinib in Human Plasma and Its Application to Clinical Pharmacokinetic Study

ABSTRACT

Mobocertinib is a potent selective tyrosine kinase inhibitor approved for the treatment of non–small cell lung cancer with activating EGFR exon 20 insertions. The aim of this study was to develop a procedure for liquid chromatography tandem mass spectrometry (LC‐MS/MS) for the determination of mobocertinib and its metabolite desmethyl‐mobocertinib in human plasma. The human plasma samples were precipitated with acetonitrile and analyzed using a Waters ACQUITY BEH C₁₈ column coupled to a triple quadrupole mass spectrometer. Separation was executed using the acetonitrile–0.1% formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Mobocertinib and desmethyl‐mobocertinib were monitored by multiple reaction monitoring (MRM) with m/z 586.5  >  72.2 and 572.4  >  473.2, respectively. The procedure demonstrated excellent linearity (r > 0.997) within the concentration range of 0.1–200 ng/mL for both analytes. Precision in relative standard deviation was <  9.37% for mobocertinib and <  12.03% for desmethyl‐mobocertinib. Accuracy in relative error was within −7.23% to 9.18% for mobocertinib and −2.78% to 9.87% for desmethyl‐mobocertinib. Extraction recovery was >  80% for both analytes. The validated LC‐MS/MS method was successfully applied to the pharmacokinetic study of mobocertinib and desmethyl‐mobocertinib in healthy human volunteers with K₂EDTA as anticoagulant after a single dose of mobocertinib (160 mg).